Akụkọ

Alpha Lifetech na-enye ndị ọkachamara nucleic acid aptamer synthesis na ọrụ ngwa, na-eme ka nyocha ngwa ngwa nke ndị aptamers nwere nkọwa dị elu.

Alpha Lifetech na-eji ọganihu kachasị ọhụrụ na teknụzụ ngosi phage, na-eme ka ị nweta ụzọ nyocha kachasị ntụkwasị obi na nke ọma maka peptides dị elu.

Nkà na ụzụ na-edezi mkpụrụ ndụ ihe nketa bụ mgbanwe ezubere iche maka usoro mkpụrụ ndụ ihe nketa na okwu mkpụrụ ndụ ihe nketa site na usoro mgbanwe mkpụrụ ndụ ihe nketa. Ọ nwere ike ịkụpụ, dochie, tinye, ma ọ bụ gbanwee ụfọdụ mkpụrụ ndụ ihe nketa nwere nkwarụ iji nweta ebumnuche ọgwụgwọ.

Alpha Lifetech nọ n'ihu n'ihu na ikpo okwu nyocha nke aptamer, na-enye ọkachamara n'ịzụlite aptamers maka ngwa dị iche iche na nyocha, nchọpụta, na ọgwụgwọ.

Nkọwa zuru oke nke CAR-T Therapy vs TCR-T Cell Therapy: Nkọwa, Usoro, Ọdịiche na Ngwa.

Ngosipụta Ngosipụta Nkà na ụzụ: Nnyocha atụmanya ahịa na ọganihu nyocha

Aha akwụkwọ: CD47 abụọ na mgbochi PD-L1 na-ebute mgbochi tumor site na sel CD8+ T intratumoral.

Na Julaị 31, 2024, na akwụkwọ akụkọ Scientific Reports, Nam Ju Lee et al. bipụtara akwụkwọ akpọrọ Otu ọbá akwụkwọ mgbochi mmadụ nke dabere na nkwụsi ike nke mmadụ VH3 scaffold.

Na Disemba 23, 2024, Fan Bu et al. bipụtara akwụkwọ akpọrọ "Nchọpụta Nanosota-EB1 na -EB2 dị ka Novel Nanobody Inhibitors Against Ebola Virus Infection" na akwụkwọ akụkọ PLOS Pathogens.

Na Septemba 12, 2024, Carli M. Stewart na ndị ọrụ ibe bipụtara akụkọ dị mkpa na Nature Communications, na-akọwapụta ọrụ nke Interleukin-4 (IL-na-ebu ike ọgwụgwụ nke sel CD8+ CAR T, akụkụ dị mkpa nke ọgwụgwọ cell CAR T. Ọganihu a nwere ike inwe nnukwu ramifications maka ụlọ ọrụ dị ka Alpha Lifetech Incorporation na-arụ ọrụ immunotherapy.